drugset / Trial / NCT04887870
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
NaSingle-groupOpen-labelTreatment
Summary
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Timeline
- Start
- 2021-06-29
- Primary completion
- 2025-04-21
- Completion
- 2025-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitravatinib | Small molecule | — | — |
| Background | Enfortumab Vedotin | Other / unclassified | — | — |
| Background | Ipilimumab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |